The Lancet14d
Evaluating the benefits of the early use of GLP-1 receptor agonists
Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
The Lancet16d
Movement disorders in 2024: peripheral and outside the box
dGraduate Institute of Biomedical Engineering, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan eGraduate Institute of Molecular Medicine, and Graduate Institute of ...
Pharmaceutical Technology1mon
Lixisenatide by Sanofi for Parkinson’s Disease: Likelihood of Approval
Lixisenatide is under clinical development by Sanofi and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition ...
ahajournals.org7y
Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus
The trial was designed to assess the efficacy and safety of lixisenatide, a glucagon-like peptide-1 receptor agonist, with respect to cardiovascular morbidity and mortality. 5 Sampling of BNP and ...